Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior : loses U.S. district court battle, copycat launches imminent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 02:29am EDT

(Reuters) - Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share "in the immediate future" to generic versions of Suboxone.

Earlier this month, a mandate by the U.S. Court of Appeals for the Federal Circuit opened the gates to rivals including India's Dr. Reddy's.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LTD -0.04% 2627.6 End-of-day quote.0.46%
INDIVIOR -7.13% 42.61 Delayed Quote.-62.07%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
12:16pLONDON STOCK EXCHANGE : Chinese data, Antofagasta help FTSE 100 end longest losi..
RE
10:19aINDIVIOR : U.S. Court Finds No Patent Violation in Rivals' Generic Medicine
DJ
07/12INDIVIOR : RB reaches settlement to fully resolve all federal investigations
AQ
07/12Reckitt Benckiser Is Fined $1.4 Billion In U.S. Opioids Case -- WSJ
DJ
07/12INDIVIOR : soars as generic copies fail to torpedo its market share
AQ
07/12INDIVIOR : Reckitt to cough up $1.4bn in US drug settlement
AQ
07/11Reckitt to Pay $1.4 Billion to Settle U.S. Opioid-Addiction Drug Probes -- 5t..
DJ
07/11INDIVIOR : Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment pr..
RE
07/11Reckitt to Pay $1.4 Billion to Settle U.S. Opioid-Addiction Drug Probes -- 4t..
DJ
07/11LONDON STOCK EXCHANGE : FTSE 100 drops as healthcare giants overshadow Fed-drive..
RE
More news
Financials (USD)
Sales 2019 716 M
EBIT 2019 145 M
Net income 2019 -
Finance 2019 381 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -7,90x
EV / Sales2019 0,01x
EV / Sales2020 0,38x
Capitalization 389 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 0,66  $
Last Close Price 0,53  $
Spread / Highest target 40,6%
Spread / Average Target 24,5%
Spread / Lowest Target -6,28%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-62.07%433
MERCK KGAA AG2.78%45 382
WUXI APPTEC CO LTD21.43%15 091
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD28.17%9 583
KYOWA HAKKO KIRIN CO LTD-5.57%9 487
JAZZ PHARMACEUTICALS PLC7.40%7 829